Laboratory models of regional chemotherapy

References

• Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996; 74: 533–536
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules in the tumor interstitium: A review. Cancer Res 1987; 47: 3039–3051
   PubMed Web of Science ®Google Scholar
• Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2: 266–276
   PubMed Web of Science ®Google Scholar
• Jain RK, Fenton BT. Intratumoral lymphatic vessels: A case of mistaken identity or malfunction?. J Natl Cancer Inst 2002; 94: 417–421
   PubMedGoogle Scholar
• Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83: 551–555
   PubMed Web of Science ®Google Scholar
• Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach. Eur J Surg Oncol 1996; 22: 152–157
   PubMedGoogle Scholar
• De Wilt JHW, Manusama ER, Van Tiel ST, Van Ijken MGA, ten Hagen TLM, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 161–166
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS. In-transit melanoma: The role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004; 199: 419–427
   PubMed Web of Science ®Google Scholar
• Canter RJ, Zhou R, Kesmodel SB, Zhang Y, Heitjan DF, Glickson JD, Leeper DB, Fraker DL. Metaiodobenzyl-guanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. Ann Surg Oncol 2004; 11: 265–273
   PubMed Web of Science ®Google Scholar
• Bauer TW, Gutierrez M, Dudrick DJ, Li J, Blair IA, Menon C, Fraker DL. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery 2003; 133: 420–428
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Vermeulen CE, Eggermont AM, Ten Hagen TL. Cytokines and vascular permeability: An in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells. Cell Biochem Biophys 2006; 44: 157–170
   PubMedGoogle Scholar
• De Brauw LM, Van de Velde CJ, Tjaden UR, de Bruijn EA, Bell AV, Hermans J, Zwaveling A. In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res 1988; 44: 137–145
   PubMed Web of Science ®Google Scholar
• Van Ijken MG, Van Etten B, de Wilt JH, Van Tiel ST, ten Hagen TL, Eggermont AM. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000; 23: 449–455
   PubMed Web of Science ®Google Scholar
• Weksler B, Schneider A, Ng B, Burt M. Isolated single lung perfusion in the rat: An experimental model. J Appl Physiol 1993; 74: 2736–2739
   PubMed Web of Science ®Google Scholar
• Wang HY, Port JL, Hochwald SN, Burt ME. Revised technique of isolated lung perfusion in the rat. Ann Thorac Surg 1995; 60: 211–212
   PubMed Web of Science ®Google Scholar
• Van Putte BP, Hendriks JM, Romijn S, Van Schil PE. Isolated lung perfusion for the treatment of pulmonary metastases current mini-review of work in progress. Surg Oncol 2003; 12: 187–193
   PubMedGoogle Scholar
• VanDerVeen AH, Seynhaeve ALB, Breurs J, Nooijen PTGA, Marquet RL, Eggermont AMM. In vivo isolated kidney perfusion with TNF-alpha in tumour bearing rats. Br J Cancer 1999; 79: 433–439
   PubMed Web of Science ®Google Scholar
• Asbach HW, Bersch W. The effect of in situ isolated perfusion of experimental renal tumors with cytotoxic agents in high concentration. Urol Int 1980; 35: 112–124
   PubMedGoogle Scholar
• Walther MM, Jennings SB, Choyke PL, Andrich M, Hurley K, Linehan WM, Rosenberg SA, Alexander RB. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol 1996; 14(Suppl. 1)S2–7, S2–7
   PubMedGoogle Scholar
• Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ, Rosenzweig A. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95: 5251–5256
   PubMed Web of Science ®Google Scholar
• Davidson MJ, Jones JM, Emani SM, Wilson KH, Jaggers J, Koch WJ, Milano CA. Cardiac gene delivery with cardiopulmonary bypass. Circulation 2001; 104: 131–133
   PubMed Web of Science ®Google Scholar
• De Vries MR, Rinkes IH, Van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Vahrmeijer AL, Eggermont AM. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: Experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998; 147: 107–119
   PubMedGoogle Scholar
• Eggermont AM, Van Ijken MG, Van Etten B, van dS, Jr., ten Hagen TL, Wiggers T, Oudkerk M, de Boeck G, de Bruijn EA. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: From laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000; 47: 776–781
   PubMed Web of Science ®Google Scholar
• Van Ijken MGA, de Bruijn EA, de Boeck G, ten Hagen TLM, Van der Sijp JRM, Eggermont AMM. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs. Ann Surg 1998; 228: 763–770
   PubMed Web of Science ®Google Scholar
• Van Ijken MG, Van Etten B, Brunstein F, ten Hagen TL, Guetens G, de Wilt JH, de Bruijn EA, Eggermont AM. Biochemotherapeutic strategies and the (dis)utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques. Eur J Surg Oncol 2005; 31: 807–816
   PubMed Web of Science ®Google Scholar
• Van Etten B, Brunstein F, Van Ijken MG, Marinelli AW, Verhoef C, van dS, Jr., Guetens G, de Boeck G, de Bruijn EA, de Wilt JH, et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: A phase I and II study. Ann Surg Oncol 2004; 11: 598–605
   PubMed Web of Science ®Google Scholar
• Van Ijken MG, de Bruijn EA, Ten Hagen TL, de Boeck G, van Eijck CH, Eggermont AM. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: A pharmacokinetic study in pigs. Eur J Surg Oncol 2004; 30: 699–707
   PubMed Web of Science ®Google Scholar
• Van Ijken MG, Van Etten B, Guetens G, Ten Hagen TL, Jeekel J, De Bruijn EA, Eggermont AM, Van Eijck CH. Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: A phase I-II trial. Eur J Surg Oncol 2004; 30: 671–680
   PubMed Web of Science ®Google Scholar